Budget impact analysis of belumosudil for chronic graft-versus-host disease treatment in the United States.
Carlos R BachierJeffrey R SkaarSumudu DehipawalaBenjamin MiaoJonathan IeyoubHaya TaitelPublished in: Journal of medical economics (2022)
The model results suggest that the introduction of belumosudil to treat cGVHD would be associated with substantial cost savings when evaluating a scenario with versus without belumosudil from a US payer perspective.
Keyphrases